SEQUENTIAL CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE & IFOSFAM

医生简介:本研究的目的是评估对晚期恶性肿瘤患者分别给予两个周期的高剂量化疗（依托泊苷、顺铂和环磷酰胺），随后（异环磷酰胺、卡铂和紫杉醇）联合G-CSF（粒细胞集落刺激因子）和自体干细胞回输的可行性，评估该方案的毒性，并确定在该联合高剂量方案中紫杉醇的最大耐受剂量。医师资格概述：组织学证实的乳腺癌、卵巢癌、软组织肉瘤、恶性黑色素瘤、骨肉瘤、尤因氏肉瘤、威尔姆氏肿瘤、胃肠道恶性肿瘤或小细胞癌的诊断；患者必须在没有疾病证据的情况下进行手术，或者在任何化疗、放疗或免疫治疗方案中都有完全缓解或部分缓解；生理年龄大于等于18岁，小于等于55岁；必须达到或超过Karnofsky性能状态的80%（患者可以通过努力进行正常活动，一些疾病的迹象或症状）。

Physician Abstract: The objectives of this study are to evaluate the feasibility of administering two cycles of high dose chemotherapy (etoposide, cisplatin and cyclophosphamide) followed by (ifosfamide, carboplatin and taxol) each combined with G-CSF (Granulocyte Colony Stimulating Factor) and autologous stem cell reinfusion to patients with advanced malignancies, to evaluate the toxicities of such a regimen, and to define the maximum tolerated dose of taxol deliverable in this combined high dose regimen. Physician Eligibility Summary: Histologically proven diagnosis of Breast Cancer, ovarian Cancer, Soft Tissue Sarcoma, Malignant Melanoma, Osteosarcoma, Ewings's Sarcoma, Wilm's Tumor, Gastrointestinal Malignancies, or Small Cell Carcinoma; Patient must be surgically with No Evidence of Disease or must have had a Complete Response or Partial Response on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen; Physiologic age greater than or equal to 18 and less than or equal to 55; Must meet or exceed a Karnofsky Performance Status of 80% (Patient can carry on normal activity with effort, some signs or symptoms of disease).